Flagship commits $50M to new startup that scours viral proteins for new drugs
In the midst of the Covid-19 pandemic, while most scientists were busy plotting new ways to combat viruses, one startup quietly began a counterintuitive campaign: getting viruses to work for us, instead of against us.
Now, after three years in stealth, Prologue Medicines launched Tuesday morning and unveiled its plan to search through millions of viral proteins to find ones that could be repurposed as treatments for cancer, immune diseases, and metabolic conditions. The Cambridge, MA startup is backed with $50 million from Flagship Pioneering, the life science venture firm that’s built dozens of biotech companies, including Moderna.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
